Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 2/20 | 0.41 |
| ▸ | GAA | P10253 | 1/20 | 0.41 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.41 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.41 |
| ▸ | CCR8 | P51685 | 1/20 | 0.40 |
| ▸ | RAB9A | P51151 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.37 |
| ▸ | ATM | Q13315 | 1/20 | 0.37 |
| ▸ | MAPT | P10636 | 1/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Trifluoroacetic Acid SCHEMBL444415 | 0.99 | KCNH2 (0.41) | KMT2AGAAKCNH2HRH3CCR8 | |
| SCHEMBL223654 | 0.93 | KMT2A (0.46) | KMT2AGAAKCNH2HRH3CCR8 | |
| SCHEMBL223649 | 0.92 | KCNH2 (0.46) | KMT2AGAAKCNH2HRH3CCR8 | |
| Trifluoroacetic Acid SCHEMBL222396 | 0.88 | HRH3 (0.35) | KCNH2HRH3RAB9A | |
| Trifluoroacetic Acid SCHEMBL2421558 | 0.86 | KDM4E (0.52) | ALDH1A1MAPTSMN1; SMN2 | |
| Trifluoroacetic Acid SCHEMBL222744 | 0.85 | RAB9A (0.41) | KMT2AHRH3RAB9AALDH1A1TDP1 | |
| Cyclohexane SCHEMBL2428515 | 0.85 | HRH3 (0.40) | KCNH2HRH3RAB9A | |
| Trifluoroacetic Acid SCHEMBL219824 | 0.84 | NPC1 (0.43) | KMT2AKCNH2HRH3RAB9AALDH1A1 | |
| Trifluoroacetic Acid SCHEMBL2417740 | 0.81 | NTRK1 (0.38) | KCNH2HRH3 | |
| Trifluoroacetic Acid SCHEMBL222702 | 0.81 | HRH3 (0.35) | KMT2AKCNH2HRH3CCR8RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120065234-A1 | SUBSTITUTED N-PHENYL-BIPYRROLIDINE CARBOXAMIDES AND THERAPEUTIC USE THEREOF | SANOFI (FR) | 2012-03-15 | — | — | US | disclosed |
| US-8088808-B2 | Substituted N-phenyl-bipyrrolidine carboxamides and therapeutic use thereof | SANOFI (FR) | 2012-01-03 | — | — | US | disclosed |
| EP-2212283-B1 | SUBSTITUTED N-PHENYL-BIPYRROLIDINE CARBOXAMIDES AND THERAPEUTIC USE THEREOF | SANOFI SA (FR) | 2011-09-21 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120065234-A1 | SUBSTITUTED N-PHENYL-BIPYRROLIDINE CARBOXAMIDES AND THERAPEUTIC USE THEREOF | HRH3, HRH4, CNR1 | KMT2A 507/4885GAA 3600/4885KCNH2 1508/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.